EP0000134A1 - Glycoprotéine, son procédé de préparation, son emploi pour la production de l'antisérum et l'antisérum - Google Patents

Glycoprotéine, son procédé de préparation, son emploi pour la production de l'antisérum et l'antisérum Download PDF

Info

Publication number
EP0000134A1
EP0000134A1 EP78100134A EP78100134A EP0000134A1 EP 0000134 A1 EP0000134 A1 EP 0000134A1 EP 78100134 A EP78100134 A EP 78100134A EP 78100134 A EP78100134 A EP 78100134A EP 0000134 A1 EP0000134 A1 EP 0000134A1
Authority
EP
European Patent Office
Prior art keywords
glycoprotein
solution
molecular weight
protein
acetylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP78100134A
Other languages
German (de)
English (en)
Other versions
EP0000134B1 (fr
Inventor
Hans Dr. Bohn
Wilhelm Winckler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of EP0000134A1 publication Critical patent/EP0000134A1/fr
Application granted granted Critical
Publication of EP0000134B1 publication Critical patent/EP0000134B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/851—Placenta; amniotic fluid

Definitions

  • the invention relates to a new glycoprotein that can be detected in blood serum, urine and in the extract of human placentas and isolated therefrom, and a method for its production.
  • the protein solution obtainable by the aqueous extraction of human placentas contains a large number of components, some of which can be assigned to the serum proteins and some of which are tissue proteins.
  • the object of the invention is to isolate a serum glycoprotein, which is not yet known, from the extract of human placentas, so that antisera directed specifically against the new glycoprotein can be produced, with which the glycoprotein in the serum and in the urine can be qualitatively detected or quantified .
  • the invention relates to a new glycopronein; which is available from blood serum, urine and the extract of human placentas. It is characterized by a protein content, essentially consisting of ⁇ -amino acids of 75 ⁇ 6%, a carbohydrate content of 24.6 ⁇ 5.2 of which hexoses 8.9 ⁇ 2%, N-acetylated hexosamine 7.1 t 1.5%, fucose 0.2 ⁇ 0.2%, N-acetylated neuraminic acid 8.4 ⁇ 1.5%, a sedimentation coefficient s 20w of 2.5 ⁇ 0.3 S, a molecular weight of 35,000 ⁇ 5,000 based on the determination in the ultracentrifuge or a molecular weight of 65,000 ⁇ 10,000 based on the determination in the sodium dodezyl sulfate-containing Polyacrylamide gel, an isoelectric point of pH 3.4 ⁇ 0.4, an extinction coefficient E (280 nm) of 1.9 ⁇ 0.3, an electrophoretic mobility
  • the sediment equilibrium method and the polyacrylamide gel electrophoresis were used to determine the molecular weights.
  • the determination in the ultracentrifuge was carried out at 9,000 rpm.
  • the evaluation was carried out on the basis of a partial specific volume of 0.74 mg / g. In the Ultracentrifuge resulted in a molecular weight of 35,000 ⁇ 5,000.
  • the isoelectric point was determined using a column (440 ml) from LKB Sweden.
  • the so-called ampholine mixture had a pH range of 2.5 to 4.0 when examining the glycoprotein.
  • the electrophoretic mobility was examined in the micromodification by Beckmann Instruments on cellulose acetate films with sodium diethyl barbiturate buffer pH 8.6.
  • the amino acid analysis was carried out according to S. Moore, DH Spackmann, WH Stein, Anal. Chem. 30, page 1185, (1958), using the Multichrom B liquid chromatograph from Beckmann. 1/2 cystine was obtained after oxidation of the proteins with performic acid (S. Moore et al., Anal. Chem. 30, page 1185, (1958)) and subsequent chromatography (S. Moore, J.Biol.Chem. 238, page 235 , (1963)) as cysteic acid.
  • the tryptophan content is with direct photometric determination according to H. Edelhoch, Biochemistry 6, page 1948, (1967).
  • the simplest way of immunologically characterizing the substance is with a known diffusion method in which antigen, i.e. the glycoprotein and an antibody directed against the glycoprotein or the antiserum not enriched with respect to the antibodies against one another in a carrier medium, such as e.g. Agar, diffuse. If the two reaction components meet in a favorable ratio, a visible precipitate forms. According to this knowledge, it is obvious to the person skilled in the art that all immunological techniques for the detection and determination of both the new glycoprotein and the antibodies directed against the glycoprotein are possible.
  • the Laurell technique is a simple and generally sufficiently precise method for the quantitative determination of glycoprotein in body fluids or in tissue extracts. It is described in analyte. Biochem. (New York), 15, page 45 (1966).
  • the invention furthermore relates to a process for the preparation of the glycoprotein characterized above, characterized in that body fluids or extracts from organs which contain the glycoprotein are fractionated on the basis of the following criteria found according to the invention.
  • the glycoprotein can be precipitated with neutral salts.
  • ammonium sulfate usually used for such precipitations, it is precipitated at a saturation concentration of 30 to 60% of the salt in a pH range near the neutral point.
  • the glycoprotein can of substances with Molecular weights between 25,000 and 75,000 are suitable.
  • the methods of gel filtration or ultrafiltration are advantageously used for this.
  • the glycoprotein is adsorbed onto weakly basic ion exchangers at neutral or weakly alkaline pH.
  • a comparatively less concentrated buffer solution is advantageously used, because the adsorption can be prevented by increasing the salt concentration or also by lowering the pH.
  • this behavior is known, there is the possibility of adsorbing the glycoprotein and eluting it using more concentrated salt solutions or buffer solutions with a reduced pH.
  • the new glycoprotein is not precipitated with the water-soluble organic bases of the acridine and quinoline series, which are usually used for protein precipitation processes. It remains in the aqueous supernatant in the concentrations customary in this process. Thereafter, an acridine base such as 2-ethoxy-6,9-diaminoacridine lactate or a quinoline base such as bis (2-methyl-4-aminoquinolyl-6) carbamide hydrochloride can be used to precipitate accompanying proteins, the glycoprotein according to the invention excess remains.
  • an acridine base such as 2-ethoxy-6,9-diaminoacridine lactate or a quinoline base such as bis (2-methyl-4-aminoquinolyl-6) carbamide hydrochloride
  • hydroxyapatite as an adsorbent for proteins.
  • the new glycoprotein shows no affinity for hydroxyapatite, whereas a number of accompanying proteins are retained by hydroxyapatite.
  • the glycoprotein is therefore one of the hydroxylapatite-passing globulins.
  • the inventor suggests to call it hydroxylapatite passing globulin (HPG-2).
  • the preparative zone electrophoresis can be used for the enrichment or isolation of the glycoprotein.
  • the affinity of the glycoprotein due to its immunological behavior can be used to enrich the glycoprotein with the help of so-called immune adsorption processes.
  • an immunoadsorbent i.e. a carrier-bound antibody against which new glycoprotein are produced, which is able to bind the glycoprotein specifically.
  • the glycoprotein can then be eluted again by changing the milieu conditions, as described several times in the specialist literature.
  • the substances according to the invention can be isolated by means of a selected combination of the methods mentioned, which on the one hand lead to the enrichment of the glycoprotein and on the other hand to a separation of other accompanying proteins. Accordingly, the subject of the present invention is in the individual enrichment steps. to be seen for the new glycoprotein and in the processes for its purification resulting from the combination of the enrichment measures.
  • the guideline for the process for the production of the glycoprotein is that the portion is obtained which gives a positive immunological reaction with an antiserum directed against the new glycoprotein.
  • the glycoprotein is still contaminated by other immunologically detectable accompanying proteins.
  • the impurities are removed by their specific adsorption.
  • You use yourself common techniques of immunoadsorption in which, according to the methods described, antibodies bound to a carrier against the protein to be removed are used as adsorbents.
  • the largely pure new glycoprotein is still associated with traces of the pregnancy-specific ⁇ 1 glycoprotein and / or the ⁇ 1 B glycoprotein, also known as easily precipitated a 1 glycoprotein.
  • immunoglobulins directed against the proteins and which are covalently bound to crosslinked agar preparations such as, for example, SEPHAROSE, can be used.
  • the protein solution applied to a column which has been filled with the specific immunoadsorbent passes through the column undisturbed insofar as only those components against which the carrier contains an immunologically active partner are bound. In this way, the new glycoprotein can be freed from the impurities.
  • the new glycoprotein To produce the new glycoprotein, several of the measures listed are combined with one another and in each case the fraction is further processed in which the new glycoprotein can be detected immunologically, while the other fractions are discarded.
  • Any body fluid or organ extract can be used as the starting material for the production of the new glycoprotein, in which it is possible to detect the glycoprotein immunologically.
  • Extracts of human placentas are preferably used, which can be obtained by comminution and extraction with water or a dilute, advantageously a less than 10% salt solution, advantageously with a 0.5% neutral salt solution, such as sodium chloride. It is advisable to use about 1 - 5 liters of the extraction solution on 1 kg of placenta. The undissolved portions are separated from the extract by centrifugation or filtration.
  • the zone in question is cut out and eluted from the inert support material with the aid of water or aqueous salt solutions, for example a 0.5 to 1% saline solution.
  • the glycoprotein produced according to the invention has antigenic properties.
  • An immunization of animals carried out by known methods led to the formation of specific antibodies in the blood of the immunized animals. Their sera can be obtained by conventional methods and the antibodies contained therein can be enriched.
  • the antisera can be used in known immunological methods for the detection and determination of the new protein in body fluids, in particular in the blood serum.
  • 150 kg of frozen placenta are crushed and extracted with 150 l of a 0.5% aqueous sodium chloride solution.
  • the extract is adjusted to pH 8 with 2N sodium hydroxide and mixed with 50 liters of a 3% aqueous solution of diaminoethoxyacridine lactate.
  • the supernatant which contains the glycoprotein (HPG-2) according to the invention is siphoned off, mixed with 5% solid sodium chloride (11 kg) to separate the diaminoethoxyacridine lactate still in solution, filtered and obtained at 30% to the weight of the liquid - solid ammonium sulfate added and stirred well. After 1 hour the precipitate is filtered off.
  • 500 g of the precipitate collected on the filter are dissolved in 500 ml of distilled water and dialyzed against a 0.01 molar tris (oxymethyl) aminomethane-hydrochloric acid buffer solution of pH 7.0, which contains 0.05% sodium azide .
  • the dialyzed solution is centrifuged and the supernatant is made up to 2,000 ml with the same buffer solution, adjusted to pH 8.0 with 0.1N sodium hydroxide solution and stirred with 500 g of moist diethylaminoethyl cellulose (Serva, Heidelberg) for 1 hour.
  • diethylaminoethyl cellulose is separated from the solution by filtration, washed twice with 1 liter of 0.01 molar tris (oxymethyl) aminomethane-hydrochloric acid buffer with a pH of 8.0 and then three times with 500 ml of 0.02 molar Tris (oxymethyl) aminomethane hydrochloric acid buffer, pH 6.5, which contains: 0.85% sodium chloride and 0.05% sodium azide; eluted.
  • the eluates are then tested with specific antiserum, the fractions containing the glycoprotein (HPG-2) are collected and the proteins are precipitated again with 30% solid ammonium sulfate, as described above.
  • the precipitate is dissolved in 50 ml of water, dialyzed against a 0.005 m phosphate buffer, pH 6.8, and placed on a 3 ⁇ 23 cm column filled with hydroxyapatite.
  • the column is developed using the 0.005 m phosphate buffer, pH 6.8.
  • the glycoprotein (HPG-2) appears in the run; this is concentrated on an ultrafilter.
  • the concentrate is then dialyzed against a 0.01 M Tris-HCl buffer, pH 7.0, and adsorbed on DEAE-SEPHADEX (column 3 ⁇ 23 cm).
  • a NaCl gradient of 0-2% is used to elute and separate the adsorbed proteins.
  • the eluate fractions containing the glycoprotein (HPG-2) are concentrated together.
  • the concentrated eluate is taken up in a 0.075 m ammonium bicarbonate solution and subjected to preparative zone electrophoresis.
  • the zone containing the HPG-2 is cut out after separation and eluted with physiological saline; the eluates are then concentrated on the ultrafilter.
  • the ⁇ 1 B glycoprotein still present as an impurity is removed with the aid of an appropriate immunoadsorbent.
  • an appropriate immunoadsorbent antibodies against the a 1 B glycoprotein are covalently bound to Sepharose and the adsorbent thus obtained is brought into contact with the eluate in a batch process or in a column.
  • the a 1 B glycoprotein is adsorbed onto the carrier-bound antibodies, while the glycoprotein HPG-2 remains in solution.
  • the solution, which then only contains HPG-2, is dialyzed against water and lyophilized. About 10 to 30 mg of the new glycoprotein HPG-2 are obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP78100134A 1977-06-15 1978-06-09 Glycoprotéine, son procédé de préparation, son emploi pour la production de l'antisérum et l'antisérum Expired EP0000134B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19772726886 DE2726886A1 (de) 1977-06-15 1977-06-15 Neues glykoprotein und verfahren zu dessen herstellung
DE2726886 1977-06-15

Publications (2)

Publication Number Publication Date
EP0000134A1 true EP0000134A1 (fr) 1979-01-10
EP0000134B1 EP0000134B1 (fr) 1981-10-28

Family

ID=6011534

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78100134A Expired EP0000134B1 (fr) 1977-06-15 1978-06-09 Glycoprotéine, son procédé de préparation, son emploi pour la production de l'antisérum et l'antisérum

Country Status (14)

Country Link
US (1) US4269825A (fr)
EP (1) EP0000134B1 (fr)
JP (1) JPS548717A (fr)
AT (1) AT366063B (fr)
AU (1) AU523785B2 (fr)
CA (1) CA1110617A (fr)
DE (2) DE2726886A1 (fr)
DK (1) DK267278A (fr)
ES (1) ES470653A1 (fr)
IE (1) IE47092B1 (fr)
IT (1) IT1113082B (fr)
MX (1) MX5459E (fr)
NZ (1) NZ187548A (fr)
ZA (1) ZA783431B (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037963A2 (fr) * 1980-04-10 1981-10-21 BEHRINGWERKE Aktiengesellschaft Protéine PP9, procédé de son isolation, ainsi que son utilisation
DE3114641A1 (de) * 1980-04-11 1982-02-11 Kureha Kagaku Kogyo K.K., Tokyo Immunosuppresives mittel in einer dosierungseinheit und verfahren zu seiner herstellung
EP0060491A2 (fr) * 1981-03-13 1982-09-22 BEHRINGWERKE Aktiengesellschaft Protéine PP16, procédé d'enrichissement et d'isolement ainsi que son application
EP0136093A2 (fr) * 1983-08-29 1985-04-03 Yoshio Sakagami Facteurs anti-cancereux
BG65084B1 (bg) * 2002-03-13 2007-02-28 Закрьiтое Акционерное Общество, Производственное Предприятие"Эндо-Фарм-А" Нов клас биоактивни гликопротеини

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2842467A1 (de) * 1978-09-29 1980-04-10 Behringwerke Ag Neues ubiquitaeres gewebsprotein pp tief 8
DE2946458A1 (de) * 1979-11-17 1981-06-11 Behringwerke Ag, 3550 Marburg Neues protein pp(pfeil abwaerts)11(pfeil abwaerts)
DE2952792A1 (de) * 1979-12-31 1981-07-02 Behringwerke Ag, 3550 Marburg Neues protein (pp(pfeil abwaerts)15(pfeil abwaerts)) mit immunsuppressiver wirkung
US4350687A (en) * 1980-02-10 1982-09-21 Research Corporation Platelet derived cell growth factor
US4481137A (en) * 1982-02-26 1984-11-06 Mochida Pharmaceutical Co., Ltd. Glycoproteins and processes for their production
DE3315000A1 (de) * 1983-04-26 1984-10-31 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)4(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
US4554256A (en) * 1983-07-21 1985-11-19 The Idaho Research Foundation, Inc. Antigen associated with early detection of mammalian pregnancy
DE3334405A1 (de) * 1983-09-23 1985-04-04 Behringwerke Ag, 3550 Marburg Membranassoziierte proteine (mp(pfeil abwaerts)2(pfeil abwaerts)), verfahren zu ihrer gewinnung sowie ihre verwendung
JPS60199819A (ja) * 1984-03-23 1985-10-09 Kowa Co トロンビン結合性物質およびその製法
JPS61294366A (ja) * 1985-06-24 1986-12-25 Toubishi Yakuhin Kogyo Kk 糖鎖に特異的な抗体の検出用試薬及びその使用
DE3602688A1 (de) * 1986-01-30 1987-08-06 Behringwerke Ag Verfahren zur gewinnung und herstellung eines pasteurisierten praeparates von (alpha)(pfeil abwaerts)2(pfeil abwaerts)-antiplasmin
JPH0266456A (ja) * 1988-08-31 1990-03-06 Saikin Kagaku Kenkyusho:Kk 疾病動物の一次診断方法、それに使用する診断試薬及びその製造方法
US5497003A (en) * 1995-02-15 1996-03-05 Servo Corporation Of America Pyroelectric detector array with optical filter elements

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2183151A1 (fr) * 1972-04-29 1973-12-14 Behringwerke Ag
DE2256168A1 (de) * 1972-11-16 1974-06-27 Behringwerke Ag Histidinreiches 3,8 s-alpha tief 2glykoprotein und verfahren zu seiner isolierung aus humanserum

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2183151A1 (fr) * 1972-04-29 1973-12-14 Behringwerke Ag
DE2256168A1 (de) * 1972-11-16 1974-06-27 Behringwerke Ag Histidinreiches 3,8 s-alpha tief 2glykoprotein und verfahren zu seiner isolierung aus humanserum

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 69, 103100m (1968) & Klin. Wochenschr., 46 (18), 981-6 (1968) *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037963A2 (fr) * 1980-04-10 1981-10-21 BEHRINGWERKE Aktiengesellschaft Protéine PP9, procédé de son isolation, ainsi que son utilisation
EP0037963A3 (en) * 1980-04-10 1981-10-28 Behringwerke Aktiengesellschaft Pp9 protein, method of enriching and preparing it, as well as its utilisation
DE3114641A1 (de) * 1980-04-11 1982-02-11 Kureha Kagaku Kogyo K.K., Tokyo Immunosuppresives mittel in einer dosierungseinheit und verfahren zu seiner herstellung
EP0060491A2 (fr) * 1981-03-13 1982-09-22 BEHRINGWERKE Aktiengesellschaft Protéine PP16, procédé d'enrichissement et d'isolement ainsi que son application
EP0060491A3 (en) * 1981-03-13 1983-03-30 Behringwerke Aktiengesellschaft Protein pp16, process for concentrating and isolating it, and its use
EP0136093A2 (fr) * 1983-08-29 1985-04-03 Yoshio Sakagami Facteurs anti-cancereux
EP0136093A3 (fr) * 1983-08-29 1986-07-30 Yoshio Sakagami Facteurs anti-cancereux
BG65084B1 (bg) * 2002-03-13 2007-02-28 Закрьiтое Акционерное Общество, Производственное Предприятие"Эндо-Фарм-А" Нов клас биоактивни гликопротеини

Also Published As

Publication number Publication date
AT366063B (de) 1982-03-10
DE2726886A1 (de) 1979-01-18
ZA783431B (en) 1979-06-27
MX5459E (es) 1983-08-11
AU3708678A (en) 1979-12-20
ES470653A1 (es) 1979-09-01
NZ187548A (en) 1984-05-31
DK267278A (da) 1978-12-16
IE47092B1 (en) 1983-12-14
AU523785B2 (en) 1982-08-12
DE2861256D1 (en) 1982-01-07
JPS6361319B2 (fr) 1988-11-28
IT1113082B (it) 1986-01-20
EP0000134B1 (fr) 1981-10-28
IE781198L (en) 1978-12-15
JPS548717A (en) 1979-01-23
IT7824531A0 (it) 1978-06-13
ATA433878A (de) 1981-07-15
CA1110617A (fr) 1981-10-13
US4269825A (en) 1981-05-26

Similar Documents

Publication Publication Date Title
DE2720704C2 (de) Neues Glycoprotein, Verfahren zu seiner Herstellung und seine Verwendung
EP0000134B1 (fr) Glycoprotéine, son procédé de préparation, son emploi pour la production de l'antisérum et l'antisérum
EP0123307A2 (fr) Protéine tissulaire PP4, procédé pour sa préparation et son utilisation
EP0060491B1 (fr) Protéine PP16, procédé d'enrichissement et d'isolement ainsi que son application
DE2640387C3 (de) Gewebespezifisches Protein und Verfahren zu dessen Herstellung
EP0009715B1 (fr) Protéine ubiquitaire de tissu PP8 et procédé pour sa préparation
EP0033000B1 (fr) Protéine PP15, procédé pour sa préparation et son utilisation
EP0014756B1 (fr) Protéine de tissu PP10 placenta spécifique et procédé pour son enrichissement
EP0101603B1 (fr) Protéine (PP13), procédé pour sa concentration et son obtention ainsi que son application
EP0100522B1 (fr) Protéine PP17, procédé pour sa concentration et son obtention ainsi que son application
EP0037963B1 (fr) Protéine PP9, procédé de son isolation, ainsi que son utilisation
EP0165476A2 (fr) Protéine de tissu PP18, son procédé d'obtention et son application
EP0141326B1 (fr) Protéine PP20, procédé de sa récupération et son utilisation
EP0029191B1 (fr) Protéine PP 11, procédé pour son isolation et son utilisation
DE3410694C2 (fr)
DE2718325A1 (de) Leucinreiches 3,1-s-alpha tief 2 -glykoprotein, verfahren zu dessen herstellung sowie dessen verwendung
EP0137345B1 (fr) Protéines associées aux membranes (MP-2), leur procédé d'obtention et leur application
DE2157610C3 (de) Schwangerschaftsspezifisches ß , -Glykoprotein, Verfahren zu seiner Isolierung und seine Verwendung für die Herstellung von Antiseren
DE3404563A1 (de) Gewebeprotein pp(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)9(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
DE2445677C2 (de) Hochmolekulares alpha-Globulin und Verfahren zu dessen Herstellung
AT369265B (de) Verfahren zur herstellung eines antiserums gegen ein leucinreiches 3,1s-alpha2-glykoprotein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB LU NL SE

Designated state(s): BE CH DE FR GB LU NL SE

17A Application maintained
17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE CH DE FR GB LU NL SE

Designated state(s): BE CH DE FR GB LU NL SE

REF Corresponds to:

Ref document number: 2861256

Country of ref document: DE

Date of ref document: 19820107

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19920507

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19920512

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19920514

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19920518

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19920616

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19920624

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19920630

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19920812

Year of fee payment: 15

EPTA Lu: last paid annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19930609

Ref country code: GB

Effective date: 19930609

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19930610

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19930630

Ref country code: BE

Effective date: 19930630

BERE Be: lapsed

Owner name: BEHRINGWERKE A.G.

Effective date: 19930630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19940101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19930609

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19940228

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19940301

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

EUG Se: european patent has lapsed

Ref document number: 78100134.2

Effective date: 19940110

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT